ArticleBiological procedures online2026
Evolutionary Trajectory of Radioresistance in Lung Cancer Brain Metastasis Organoids.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRadiotherapy (RT) is a cornerstone treatment for lung cancer brain metastasis (LCBM), yet acquired radioresistance frequently leads to recurrence. The molecular and metabolic mechanisms underlying this adaptive evolution at single-cell resolution remain poorly defined.
methodsPatient-derived organoids (PDOs) from LCBM tissues were established to model clinical radiation responses. Paired pre- and post-RT samples underwent single-cell RNA sequencing (scRNA-seq) to delineate transcriptional, metabolic, and regulatory alterations associated with radioresistance.
resultsSingle-cell analysis revealed substantial population remodeling following RT, characterized by depletion of proliferative cells and enrichment of a resilient Hypoxic-EMT subpopulation. Pseudotime analysis demonstrated lineage plasticity, showing a transition from proliferative to mesenchymal states. Mechanistically, a viral mimicry response involving NF-κB and STAT signaling supported stress adaptation. Resistant cells exhibited a hypermetabolic phenotype marked by metabolic plasticity, including hybrid bioenergetics coupling glycolysis with oxidative phosphorylation, enhanced lipid turnover via simultaneous fatty acid synthesis and degradation, and increased glutathione metabolism for reactive oxygen species buffering. Pharmacogenomic profiling indicated concurrent chemotherapy resistance but collateral sensitivity to PI3K/MEK inhibitors and epigenetic therapies.
conclusionsThese findings provide a high-resolution atlas of radioresistance in LCBM and suggest that targeting the Hypoxic-EMT niche or oxidative-antioxidant balance may overcome therapeutic resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.